As part of the $100 million deal, the companies will collaborate to develop more than 10 experimental drugs to treat conditions such as cardio-metabolic disorders and pain.
To expand its gene-silencing portfolio, Eli Lilly will pay $100 million upfront and buy a $100 million equity stake. Under the deal, Dicerna is eligible to receive up to $350 million and some royalties for each developed drug.
Gene-silencing technology works by targeting and turning off certain genetic material in an effort to prevent some disease-causing proteins from forming.
Johnson and Johnson has also recently invested in gene silencing firms.
More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump’s plan to lower prescription drug prices: 7 takeaways
